NCT01671332View on ClinicalTrials.gov

Docetaxel +/- Suramin in 2nd Line Advanced Non-Small Cell Lung Cancer

PHASE2CompletedINTERVENTIONAL
Enrollment

80

Participants

Timeline

Start Date

June 30, 2012

Primary Completion Date

June 11, 2015

Study Completion Date

June 16, 2016

Conditions
Carcinoma, Non Small Cell Lung
Interventions
DRUG

Docetaxel

IV over 60 minutes, 75 mg/m2

DRUG

Suramin

IV over 30 minutes

DRUG

Docetaxel

IV over 60 minutes. 56 mg/m2

Trial Locations (2)

53792

University of Wisconsin Carbone Comprehensive Cancer Center, Madison

Unknown

Medical College of Wisconsin, Milwaukee

Sponsors

Collaborators (1)

Optimum Therapeutics, LLC
All Listed Sponsors
collaborator

Medical College of Wisconsin

OTHER

collaborator

Optimum Therapeutics, LLC

INDUSTRY

collaborator

Ohio State University

OTHER

lead

University of Wisconsin, Madison

OTHER

NCT01671332 - Docetaxel +/- Suramin in 2nd Line Advanced Non-Small Cell Lung Cancer | Biotech Hunter | Biotech Hunter